Last updated: February 15, 2026
Overview of NDC 00597-0380
NDC 00597-0380 corresponds to Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate (ADC) indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Approved by the FDA in 2017, it targets CD22-positive leukemia cells.
Market Size and Growth Drivers
| Parameter |
Data |
Source |
| Market Scope |
Hematologic malignancies, primarily relapsed/refractory B-cell ALL |
[1] |
| Estimated US Phase 3 Treatment Population |
Approx. 3,000 patients annually |
[2] |
| Global Market Estimate (2022) |
$200 million |
[3] |
| Compound Annual Growth Rate (CAGR) |
12% (2022-2027) |
[4] |
The primary market is US-based, with expansion into Europe and Asia. The incidence of adult ALL in the US is approximately 1.4 per 100,000, with relapsed or refractory cases forming a smaller subset (~15-20%).
Competitive Landscape
NDC 00597-0380 faces competition from:
- Blinatumomab (Blincyto) — bispecific T-cell engager
- Infliximab (Remsima) — monoclonal antibody
- Other emerging ADCs targeting CD22 or CD19
Market share distribution favors Blinatumomab due to earlier market entry and broader indication approvals.
Pricing Trends and Projections
| Year |
Average Wholesale Price (AWP) per Dose |
Notes |
Source |
| 2022 |
~$11,000 |
Based on current package pricing |
[5] |
| 2027 (Projected) |
~$13,200 (+20%) |
Accounting for inflation, market expansion |
Internal estimate |
The current price per treatment course for inotuzumab ozogamicin is approximately $180,000, considering multiple doses over several weeks. Price adjustments are driven by:
- payer negotiations
- generic competition overload
- manufacturing cost reductions
Regulatory and Pricing Considerations
The drug is covered under FDA-approved indications, influencing pricing pressure. Payer policies are increasingly favoring value-based models, impacting profit margins.
Price projections assume no significant price erosion or policy-driven price caps before 2027. The industry trend toward biosimilars for marketed ADCs may influence future pricing, but no biosimilars are currently approved for inotuzumab ozogamicin.
Market Penetration and Revenue Forecasts
By 2027, projected annual revenues are estimated at $250 million, driven by:
- Increased awareness among oncologists
- Expanded indications (e.g., frontline therapy in clinical trials)
- Rising incidence of relapsed/refractory ALL
Market penetration is forecasted at approximately 60% of potential eligible patients by 2027, considering current utilization rates and potential expansion.
Key Price Influencers and Risks
- Policy shifts towards biosimilar substitute availability.
- Development of combination regimens potentially reducing utilization of monotherapy.
- Insurance reimbursement policies impacting patient access.
Key Takeaways
- The US market for inotuzumab ozogamicin stands at roughly $200 million in 2022, with growth expected to reach $250 million by 2027.
- Price per dose is approximately $11,000, with potential increases to $13,200 over five years.
- Competition from other targeted therapies and biosimilar emergence poses risks to pricing stability.
- Revenue projections depend on increased adoption, expanded indications, and payer policies.
FAQs
1. What factors most influence the pricing of NDC 00597-0380?
Pricing is driven by clinical efficacy, manufacturing costs, market competition, payer negotiations, and reimbursement policies.
2. How does inotuzumab ozogamicin compare with its competitors?
It competes mainly with Blinatumomab; while both target relapsed/refractory ALL, differences in administration, efficacy, and safety profiles influence market share.
3. What is the outlook for biosimilar competition?
No biosimilars are approved presently; however, biosimilar development is advancing for similar ADCs, which could impact pricing post-2027.
4. What market segments are likely to expand?
Expansion includes frontline therapy trials and combination regimens with other agents, potentially increasing the applicable patient population.
5. How might regulatory changes impact price projections?
Stricter cost-control measures or value-based pricing structures could suppress pricing growth, while expanded indications might support higher prices.
Sources
- American Cancer Society. "Key Statistics for Leukemia." 2022.
- IQVIA. "US Oncology Market Report." 2022.
- EvaluatePharma. "Global Hematology Market Outlook." 2022.
- MarketResearch.com. "Hematology/Oncology Drug Market Forecast." 2022–2027.
- Red Book. "Average Wholesale Price Data." 2022.
